Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Solutions

    Solutions

    Our solutions span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Solutions
    Cardiac Safety MonitoringClinical & Scientific OperationsConsultingEarly ClinicalLaboratoriesLanguage ServicesMedical ImagingSite & Patient Solutions Strategic SolutionsSymphony Health Technologies
    End-to-end services, operational model and technology to deliver customised solutions.
    Decentralised Clinical Trial Solutions

    End-to-end services, operational model and technology to deliver customised solutions.

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.
    Real World Intelligence®

    Optimising real world data to drive effective outcomes and achieve regulatory authorisation.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment and Public HealthMedical DevicePharmaceuticals
    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    10 October 2023
    Webinar: Taking a proactive and holistic approach to diversity assessment and planning

    10 October 2023

    12 October 2023
    Webinar: Advances in oncological imaging - Tumour growth rate modelling and radiomics

    12 October 2023

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyHealthcare IntelligenceICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON CARES is our commitment to making a positive impact on our people, environment and our community.
    Environmental, Social and Governance

    ICON CARES is our commitment to making a positive impact on our people, environment and our community.

    Clinical Research. Evolved.
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 21 June 2022

    ICON plc schedules second quarter 2022 earnings conference call

    ICON plc schedules second quarter 2022 earnings conference call on Wednesday, July 27, 2022

  • 23 May 2022

    ICON plc to present at the H.C. Wainwright Global Investment Conference and the Jefferies Healthcare Conference

    Tuesday, May 24, 2022, at 7:00am ET.

  • 23 May 2022

    ICON named Business & Finance Company of the Year and one of Forbes’ Best Employers for Diversity

    ICON kick starts the first half of 2022 with a string of prestigious industry awards recognising healthcare intelligence work and staff, as independently judged by peers worldwide

  • 3 May 2022

    ICON plc to present at the BofA Securities 2022 Healthcare Conference

    Tuesday, May 10, 2022, at 5:20pm PT.

  • 27 April 2022

    ICON reports first quarter 2022 results

    Quarter 1 adjusted revenue of $1.901.8 million representing a year on year increase of 121.6% or 125% on a constant currency basis.

  • 10 March 2022

    ICON plc to Webcast Analyst Day Meeting

    Thursday, March 17, 2022 at 12:30 ET.

  • 22 February 2022

    ICON Reports Fourth Quarter and Full Year 2021 Results

    Record net business wins in the quarter of $2,378 million; a net book to bill of 1.26. Full year net business wins of $6,958 million; a net book to bill of 1.27.

  • 18 February 2022

    ICON plc to Present at the 2022 Citi Healthcare Conference

    Thursday, February 24, 2022 at 11:45 ET.

  • 12 January 2022

    ICON Issues Financial Guidance for Full Year 2022

    Full Year 2022 adjusted earnings per share guidance in the range of $11.55 - $11.95, representing growth of 21 – 23% over Full Year 2021 adjusted earnings per share guidance.

  • 5 January 2022

    ICON plc to Present at the 40th Annual JP Morgan Healthcare Conference

    A world-leading healthcare intelligence and clinical research organisation, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 40th Annual JP Morgan Healthcare Conference

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • ...
  • 17
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
      • BioEquity Europe
    • Webinars
    • Workshops
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
  • Youtube
  • © 2023 ICON plc
  • Disclaimer
  • Privacy & Data
  • Site Cookies

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media